Could a supplement boost prostate cancer treatment?
NCT ID NCT07389174
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests whether adding a dietary supplement called LC-K76 to standard hormone therapy is safe for men with metastatic hormone-sensitive prostate cancer. Forty men will receive the supplement plus hormone therapy for 24 weeks, then be followed for another 24 weeks. The main goal is to check for side effects, but researchers will also look at PSA levels and how long it takes for the cancer to become resistant to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LC-K76 (a dietary supplement)
What this could lead to
If it works, this could point toward a way to improve standard hormone therapy for metastatic prostate cancer.
What could go wrong
This is a very early, small trial (40 people) focused on safety, not proof of effectiveness. The supplement may not provide any added benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changzheng hospital
Shanghai, Shanghai Municipality, 201109, China
Contact Phone: •••-•••-•••• Email: •••••@•••••